These categories include estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC), with TNBC distinguished by the absence of both ER expression, progesterone receptor expression, and HER2 amplification. Here, ERBB2 is linked to triple-negative breast carcinoma.